Ostro's Partnership with DTRF Enhances Patient Resources
Ostro, a leading figure in AI-driven digital engagement solutions, is excited to announce its partnership with the Desmoid Tumor Research Foundation. As we reflect on the significance of Rare Disease Month, this collaboration aims to raise awareness and promote meaningful innovation.
AI-Powered Engagement for Better Access
Through this partnership, Ostro offers its advanced AI capabilities to enhance the DTRF website. This initiative significantly improves access to critical information for those affected by desmoid tumors, including patients and their caregivers.
The AI-enabled capabilities ensure a smooth and intuitive journey for users, effectively guiding desmoid tumor community members toward the most pertinent resources and information. This solution exemplifies Ostro's commitment to using technology to create positive interactions and improved outcomes for patients with complex medical conditions.
Empowering the Patient Community
"At Ostro, our aim is to revolutionize healthcare by providing innovative and engaging experiences that yield meaningful outcomes for those we serve," stated Ahmed Elsayyad, President of Ostro. The company recognizes the vital role played by patient associations and foundations like DTRF in offering essential education and support within the rare disease community.
Collaboration with the DTRF Patient Advocacy Committee (PAC) has been instrumental in shaping the user experience. The PAC generously shared their insights and feedback to tailor the navigation experience, ensuring it meets the unique needs of the desmoid tumor community. This partnership illustrates how powerful collaboration can lead to tools that bridge information gaps in the healthcare landscape.
Gratitude for Contributions
Lynne Hernandez, Executive Director of DTRF, expressed appreciation for the PAC's dedication and Ostro's expertise. She emphasized the profound impact their joint efforts have made in creating a resource that will truly enhance the lives of those affected by desmoid tumors. Together, they are setting a benchmark for effective patient resources.
About Ostro
Ostro stands at the forefront of AI-powered digital engagement solutions, committed to aiding life sciences brands in forging meaningful connections that promote better health outcomes. By implementing cutting-edge technology, Ostro empowers organizations to engage with patients, caregivers, and healthcare providers in personalized and impactful ways.
About the Desmoid Tumor Research Foundation (DTRF)
The Desmoid Tumor Research Foundation is the sole organization in the United States focused on funding research to find a cure for desmoid tumors. DTRF works tirelessly to support and educate patients and their caregivers while advocating tirelessly for increased research and awareness regarding this rare disease.
Frequently Asked Questions
What is Ostro's role in the partnership with DTRF?
Ostro provides AI-driven digital engagement solutions to enhance the user experience on the DTRF website, improving access to resources for patients and caregivers.
How does the DTRF benefit from this collaboration?
The collaboration allows DTRF to utilize Ostro's technology to better serve the desmoid tumor community, making crucial information more accessible.
Who contributed to refining the user experience?
Members of the DTRF Patient Advocacy Committee played a vital role in shaping the user experience on the website with their insights and feedback.
What is the mission of Ostro?
Ostro's mission is to transform healthcare through innovative digital engagement that results in meaningful outcomes for patients.
What does the DTRF do for the desmoid tumor community?
The DTRF is dedicated to funding research, providing education, and supporting individuals affected by desmoid tumors while advocating for increased awareness.
